Introducing HPV Vaccine in Developing Countries ??? Key Challenges and Issues, New England Journal of Medicine, vol.356, issue.19, pp.1908-1910, 2007. ,
DOI : 10.1056/NEJMp078053
Enquête Santé Protection Sociale 2006, un panel pour l'analyse des politiques de santé, la santé publique et la recherche en économie de la santé. Questions d'économie de la santé IRDES, pp.131-132, 2008. ,
Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing, Oncology Reports, vol.10, pp.175-179, 2003. ,
DOI : 10.3892/or.10.1.175
Human Papillomavirus Genotype Distribution in External Acuminata Condylomata: A Large French National Study (EDiTH IV), Clinical Infectious Diseases, vol.47, issue.5, pp.610-615, 2008. ,
DOI : 10.1086/590560
URL : https://hal.archives-ouvertes.fr/hal-00484954
Les comportements sexuels des consultants d'un centre de dépistage anonyme et gratuit du VIH à Paris, Contraception, vol.25, pp.242-250, 1997. ,
The epidemiology of human papillomavirus infections, Journal of Clinical Virology, vol.32, pp.16-24, 2005. ,
DOI : 10.1016/j.jcv.2004.12.008
Bulletin Epidémiologique Hebdomadaire, pp.5-6, 2002. ,
Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands, Vaccine, vol.25, issue.33, pp.6245-6256, 2007. ,
DOI : 10.1016/j.vaccine.2007.05.061
The causal relation between human papillomavirus and cervical cancer, Journal of Clinical Pathology, vol.55, issue.4, pp.244-265, 2002. ,
DOI : 10.1136/jcp.55.4.244
Prevalence of Human Papillomavirus in Cervical Cancer, Obstetrical & Gynecological Survey, vol.50, issue.10, pp.796-802, 1995. ,
DOI : 10.1097/00006254-199510000-00015
Guide méthodologique pour l'évaluation économique des stratégies de santé : recommandations méthodologiques. Collège des Economistes de la santé, 2003. ,
At what age do women and men have their first sexual intercourse? World comparison and recent trends. Population and societies, pp.1-4, 2003. ,
Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection, Canadian Medical Association Journal, vol.177, issue.5 ,
DOI : 10.1503/cmaj.061709
The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada, Vaccine, vol.25, issue.29, pp.5399-5408, 2007. ,
DOI : 10.1016/j.vaccine.2007.04.086
Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients, Journal of Clinical Microbiology, vol.37, pp.3316-3322, 1999. ,
HPV and cervical cancer in the World, Report. Vaccine, vol.25, pp.1-230, 2007. ,
Chapter 3: Cofactors in Human Papillomavirus Carcinogenesis--Role of Parity, Oral Contraceptives, and Tobacco Smoking, JNCI Monographs, vol.2003, issue.31, pp.20-28, 2003. ,
DOI : 10.1093/oxfordjournals.jncimonographs.a003477
Chapter 4: Genital Tract Infections, Cervical Inflammation, and Antioxidant Nutrients--Assessing Their Roles as Human Papillomavirus Cofactors, JNCI Monographs, vol.2003, issue.31, pp.29-34, 2003. ,
DOI : 10.1093/oxfordjournals.jncimonographs.a003478
Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women, British Journal of Cancer, vol.84, issue.12, pp.1616-1623, 2001. ,
DOI : 10.1054/bjoc.2001.1845
Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis, The Lancet, vol.366, issue.9490, pp.991-998, 2005. ,
DOI : 10.1016/S0140-6736(05)67069-9
Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer, Cancer Epidemiology Biomarkers & Prevention, vol.14, issue.5, pp.1157-1164, 2005. ,
DOI : 10.1158/1055-9965.EPI-04-0812
Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis, British Journal of Cancer, vol.19, issue.1, pp.101-105, 2003. ,
DOI : 10.1016/S0140-6736(03)12120-4
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis, British Journal of Cancer, vol.88, issue.1, pp.63-73, 2003. ,
DOI : 10.1038/sj.bjc.6600688
The development of cervical cancer and its precursors: what is the role of human papillomavirus infection?, Current Opinion in Obstetrics and Gynecology, vol.18, issue.Suppl 1, pp.5-13, 2006. ,
DOI : 10.1097/01.gco.0000216315.72572.fb
Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus ,
Cervical Human Papillomavirus Infection in the Female Population in Barcelona, Spain, Sexually Transmitted Diseases, vol.30, issue.10, pp.788-793, 2003. ,
DOI : 10.1097/01.OLQ.0000080177.82204.E0
Classification of papillomaviruses, Virology, vol.324, issue.1, pp.17-27, 2004. ,
DOI : 10.1016/j.virol.2004.03.033
The papillomavirus life cycle, Journal of Clinical Virology, vol.32, pp.7-15, 2005. ,
DOI : 10.1016/j.jcv.2004.12.006
Model for Assessing Human Papillomavirus Vaccination Strategies, Emerging Infectious Diseases, vol.13, issue.1, pp.28-41, 2007. ,
DOI : 10.3201/eid1301.060438
Journal de gynécologie, obstétrique et biologie de la reproduction, pp.1-16, 1990. ,
Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High???Risk Area for Cervical Cancer, The Journal of Infectious Diseases, vol.180, issue.5, pp.1415-1423, 1999. ,
DOI : 10.1086/315086
Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases, New England Journal of Medicine, vol.356, issue.19, pp.1928-1943, 2007. ,
DOI : 10.1056/NEJMoa061760
Human papilloma virus DNA: physical mapping and genetic heterogeneity., Proceedings of the National Academy of Sciences, vol.73, issue.4, pp.1310-1313, 1976. ,
DOI : 10.1073/pnas.73.4.1310
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC430256
Cost-Effectiveness of Cervical Cancer Screening With Human Papillomavirus DNA Testing and HPV-16,18 Vaccination, JNCI Journal of the National Cancer Institute, vol.100, issue.5, pp.308-320, 2008. ,
DOI : 10.1093/jnci/djn019
Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries, Vaccine, vol.26, issue.32, pp.4080-4093, 2008. ,
DOI : 10.1016/j.vaccine.2008.04.053
From Natural History To Vaccines and Beyond. M. Saveria Campo Division of Pathological Sciences, 2006. ,
Vaccins prophylactiques antipapillomavirus??: enjeux et perspectives, Gyn??cologie Obst??trique & Fertilit??, vol.34, issue.7-8, pp.647-655, 2006. ,
DOI : 10.1016/j.gyobfe.2006.05.008
Human Papillomavirus Vaccination ??? Reasons for Caution, New England Journal of Medicine, vol.359, issue.8, pp.861-862, 2008. ,
DOI : 10.1056/NEJMe0804638
Natural History of Cervicovaginal Papillomavirus Infection in Young Women, New England Journal of Medicine, vol.338, issue.7, pp.423-428, 1998. ,
DOI : 10.1056/NEJM199802123380703
Distribution des génotypes de papillomavirus humain (HPV) dans les lésions génitales en France : études EDiTH, Bulletin Epidémiologique Hebdomadaire, pp.29-313, 2009. ,
Improvement of the quality and comparability of causes-of-death statistics inside the European Community. EUROSTAT Task Force on "causes of death statistics, pp.447-456, 1998. ,
Sociodemographic Factors Associated With High-Risk Human Papillomavirus Infection, Obstetrics & Gynecology, vol.110, issue.1, pp.87-95, 2007. ,
DOI : 10.1097/01.AOG.0000266984.23445.9c
Modeling Cervical Cancer Prevention in Developed Countries, Vaccine, vol.26, pp.76-86, 2008. ,
DOI : 10.1016/j.vaccine.2008.06.009
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States, Annals of Internal Medicine, vol.151, issue.8, pp.538-545, 2009. ,
DOI : 10.7326/0003-4819-151-8-200910200-00007
Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006???January 2008, Vaccine, vol.26, issue.51, pp.6529-6541, 2006. ,
DOI : 10.1016/j.vaccine.2008.08.067
EPIDEMIOLOGY OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION, Epidemiologic Reviews, vol.10, issue.1, pp.3-8, 1997. ,
DOI : 10.1093/oxfordjournals.epirev.a036020
A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program, Sexual Health, vol.4, issue.3, pp.165-175, 2007. ,
DOI : 10.1071/SH07043
Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs, JAMA, vol.290, issue.6, pp.781-789, 2003. ,
DOI : 10.1001/jama.290.6.781
Comparaison coût-efficacité par modélisation de l'imiquimod et de la podophyllotoxine dans le traitement du condylome acuminé externe en France, pp.731-736, 2003. ,
Koilocytes indicate a role for human papilloma virus in breast cancer, British Journal of Cancer, vol.27, issue.8, pp.1351-1356, 2009. ,
DOI : 10.1038/nrc798
Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing, International Journal of STD & AIDS, vol.17, issue.8, pp.517-521, 2006. ,
DOI : 10.1258/095646206778145550
Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata acuminata treated in vitro CO2 laser, and microwave, Journal of Dermatological Science, vol.6, issue.1, pp.209-211, 1995. ,
DOI : 10.1016/0923-1811(93)91219-K
Human papillomavirus genotype as a major determinant of the course of cervical cancer., Journal of Clinical Oncology, vol.16, issue.8, pp.2613-2619, 1998. ,
DOI : 10.1200/JCO.1998.16.8.2613
Incidence et prise en charge des condylomes acuminés externes en médecine générale, pp.991-996, 2002. ,
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices, Morbidity and Mortality Weekly Report, vol.56, pp.1-24, 2007. ,
DOI : 10.1037/e601292007-001
Efficacy of Human Papillomavirus Vaccines, International Journal of Gynecological Cancer, vol.17, issue.7, pp.1166-1176, 2009. ,
DOI : 10.1111/IGC.0b013e3181a3d100
NATURAL HISTORY OF CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS, Obstetrics & Gynecology, vol.92, issue.Supplement, pp.727-735, 1998. ,
DOI : 10.1097/00006250-199810001-00046
Pr??vention du??cancer du??col ut??rin??: enjeux et??perspectives de??la??vaccination antipapillomavirus, Gyn??cologie Obst??trique & Fertilit??, vol.34, issue.3, pp.189-201, 2006. ,
DOI : 10.1016/j.gyobfe.2006.01.036
Pr??vention du??cancer du??col ut??rin??: enjeux et??perspectives de??la??vaccination antipapillomavirus, Gyn??cologie Obst??trique & Fertilit??, vol.34, issue.3, pp.189-201, 2006. ,
DOI : 10.1016/j.gyobfe.2006.01.036
Impact of HPV infection in adolescent populations, Journal of Adolescent Health, vol.37, issue.6, pp.3-9, 2005. ,
DOI : 10.1016/j.jadohealth.2005.09.011
Chapter 5: Updating the natural history of HPV and anogenital cancer, Vaccine, vol.24, pp.42-51, 2006. ,
DOI : 10.1016/j.vaccine.2006.06.018
Histoire du suivi cytologique de 148 femmes atteintes d???un cancer invasif du col ut??rin, Gyn??cologie Obst??trique & Fertilit??, vol.30, issue.3, pp.210-217, 2002. ,
DOI : 10.1016/S1297-9589(02)00297-7
Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product, The EMBO Journal, vol.8, pp.4099-4105, 1989. ,
Against which human papillomavirus types shall we vaccinate and screen? the international perspective, International Journal of Cancer, vol.183, issue.2, pp.278-285, 2004. ,
DOI : 10.1002/ijc.20244
Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer, New England Journal of Medicine, vol.348, issue.6, pp.518-527, 2003. ,
DOI : 10.1056/NEJMoa021641
Chapter 1: HPV in the etiology of human cancer, Vaccine, vol.24, pp.1-10, 2006. ,
DOI : 10.1016/j.vaccine.2006.05.115
A summary of the 25th International Papillomavirus Conference 2009: Vaccines, screening, epidemiology and therapeutics, Journal of Clinical Virology, vol.47, issue.3, pp.208-215, 2010. ,
DOI : 10.1016/j.jcv.2009.12.005
Comité consultatif mondial de la sécurité vaccinale, 17-18 décembre, pp.37-40, 2008. ,
Vaccins anti-papillomavirus humain, note d'information de l'OMS. Relevé épidémiologique hebdomadaire, pp.118-131, 2009. ,
Natural History of Cervical Intraepithelial Neoplasia, International Journal of Gynecological Pathology, vol.12, issue.2, pp.186-192, 1993. ,
DOI : 10.1097/00004347-199304000-00018
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, The Lancet, vol.374, issue.9686, pp.301-314, 2009. ,
DOI : 10.1016/S0140-6736(09)61248-4
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort, British Journal of Cancer, vol.88, pp.942-953, 2004. ,
DOI : 10.1038/sj.bjc.6602049
Distribution of human papillomavirus (HPV) genotypes in genital warts from males in Slovenia, Acta Dermatovenerologica Alpina, vol.16, pp.91-96, 2007. ,
Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study, International Journal of Cancer, vol.367, issue.Suppl 3, pp.424-427, 2008. ,
DOI : 10.1002/ijc.23093
Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study, International Journal of Cancer, vol.367, issue.Suppl 3, pp.428-432, 2008. ,
DOI : 10.1002/ijc.23092
Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2 ,
Cancer incidence and mortality in France over the period 1978-2000. Revue d'épidémiologie et de Santé Publique, pp.3-30, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-00427472
??pid??miologie et histoire naturelle de l???infection g??nitale ?? papillomavirus humain, Gyn??cologie Obst??trique & Fertilit??, vol.30, issue.2, pp.139-146, 2002. ,
DOI : 10.1016/S1297-9589(01)00282-X
Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA, The Lancet, vol.335, issue.8699, pp.1171-1174, 1990. ,
DOI : 10.1016/0140-6736(90)92693-C
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine, analysis of a randomised placebo-controlled trial up to 6.4 years, Lancet, vol.374, pp.1975-1985, 2009. ,
Vaccin contre les papillomavirus : Cibler les adolescentes de 14 ans, Concours médical 2007, pp.846-849 ,
Ancelle-Park R. Evaluation du dépistage organisé et du dépistage individuel du cancer du col de l'utérus : utilité des données de l'Assurance maladie, Bulletin Epidémiologique Hebdomadaire, pp.19-81, 2002. ,
EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary, Annals of Oncology, vol.14, issue.90005, pp.61-118, 2003. ,
DOI : 10.1093/annonc/mdg754
HPV Vaccination ??? More Answers, More Questions, New England Journal of Medicine, vol.356, issue.19, pp.1991-1993, 2007. ,
DOI : 10.1056/NEJMe078060
Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix??, Advances in Therapy, vol.26, issue.suppl.2, pp.983-998, 2009. ,
DOI : 10.1007/s12325-009-0079-5
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update, International Journal of Cancer, vol.189, issue.3, pp.621-632, 2007. ,
DOI : 10.1002/ijc.22527
Les vaccinations : rapport coût-efficacité. Revue Médicale de Bruxelles, pp.451-458, 2009. ,
Evaluating Human Papillomavirus Vaccination Programs, Emerging Infectious Diseases, vol.10, issue.11, pp.1915-1923, 2004. ,
DOI : 10.3201/eid1011.040222
URL : http://doi.org/10.3201/eid1011.040222
Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: A literature review, Vaccine, vol.26, issue.49, pp.6258-6265, 2008. ,
DOI : 10.1016/j.vaccine.2008.09.036
Vaccination HPV pour la prévention du cancer du col de l'utérus en Belgique: Health Technology Assessment, KCE report, vol.64, issue.152, 2007. ,
Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty, American Journal of Epidemiology, vol.165, issue.7, pp.762-775, 2007. ,
DOI : 10.1093/aje/kwk059
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up, British Journal of Cancer, vol.17, issue.11, pp.1459-1466, 2006. ,
DOI : 10.1093/aje/kwf180
New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections, European Journal of Cancer, vol.38, issue.17, pp.2229-2242, 2002. ,
DOI : 10.1016/S0959-8049(02)00462-8
Management of anogenital warts (condylomata acuminata), European Journal of Dermatology, vol.11, pp.598-603, 2001. ,
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, The Journal of Pathology, vol.89, issue.1, pp.12-19, 1999. ,
DOI : 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
WHO Guide for standardisation of economic evaluations of immunization programmes, Vaccine, vol.28, issue.11, pp.2356-2359, 2010. ,
DOI : 10.1016/j.vaccine.2009.06.035
Chapter 5: Viral and Host Factors in Human Papillomavirus Persistence and Progression, JNCI Monographs, vol.2003, issue.31, pp.35-40, 2003. ,
DOI : 10.1093/oxfordjournals.jncimonographs.a003480
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study, The Lancet, vol.357, issue.9271, pp.1831-1836, 2001. ,
DOI : 10.1016/S0140-6736(00)04956-4
Dépistage du cancer du col de l'utérus, Baromètre cancer 2005. Editions Inpes. Inpes, pp.128-164, 2006. ,
In : International Comittee on the Taxonomy of Viruses "Virus Taxonomy. Classification and nomenclature of viruses" 8 th report, pp.293-253, 2005. ,
Infections à papillomavirus. État des connaissances, pratiques et prévention vaccinale, 2006. ,
Traité des infections et pathologies génitales à papillomavirus, 2007. ,
DOI : 10.1007/978-2-287-72066-6
Les papillomavirus humains et leur r??le dans l???histoire naturelle du cancer du col de l???ut??rus. Perspectives dans le domaine de la pr??vention de ce cancer ,
DOI : 10.1007/2-287-28699-3_1
Place de la vaccination contre les papillomavirus humains en France, 2006. ,
Les comportements sexuels en France. La documentation française, 1993. ,
Papillomavirus infections in human pathology, 2000. ,
Recommandations Relatives au Programme de Vaccination Contre le Virus du Papillome. Comité canadien d'immunisation, 2007. ,
Accréditation en Santé, Anaes. Conduite à tenir devant une patiente ayant un frottis cervico-utérin anormal, 2002. ,
Estimation nationale de l''incidence et de la mortalité par cancer en France entre, p.132, 1980. ,
Health Concerns Following HPV -Vaccine Safety, Atlanta. Advisory Committee on Immunization Practices (ACIP), pp.45-59, 2008. ,
Avis relatif à la vaccination antipapillomavirus type 16 et 18, 2006. ,
Avis relatif à la vaccination contre les papillomavirus humains 6, pp.16-18, 2007. ,
Données épidémiologiques sur le cancer du col de l'utérus, p.33, 2008. ,
Plan Cancer, 2009. ,
Note de cadrage : Stratégie de dépistage du cancer du col de l'utérus en France en, 2009. ,
Cresge) Modélisation médico-économique de l'impact de l'organisation du dépistage du cancer du col utérin et de l'introduction de la vaccination contre les HPV dans le calendrier vaccinal. InVS : Saint-Maurice, 2007. ,
Données mondiales sur la vaccination. Organisation Mondiale de la Santé, 2009. ,
Vaccins et vaccination: la situation dans le monde, 2009. ,
World development report 1993 : investing in health, 1993. ,
Okonomische Evaluation der Impfung gegen humane Papillomaviren (HPV-Impfung) in Osterreich. HTA Projektbericht n° 009, p.126, 2007. ,
EPARs for authorised medicinal products for human use. Cervarix. Disponible sur http, 2010. ,
EPARs for authorised medicinal products for human use. Gardasil. Disponible sur http, 2010. ,
Disponible sur http://www.afd-ld.org/~fdp_viro/content.php?page=papillomavirus (dernière consultation mars, 2010. ,
Vaccines and Related Biological Products Advisory Comitee meeting, 2009. Briefing information, 2009. ,